First-in-human results prompt a biomarker-defined approach for CID-078.
ApexOnco Front Page
Recent articles
AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
After a phase 3 push the livmoniplimab plan falters.
A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
The company discontinues one of its two KRAS G12D degraders.
With a slashed valuation the newly listed biotech heads for phase 3.
An actinium-based backup and Werner helicase inhibitor are notable absences.
